Vertex Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 4/6

Vertex Pharmaceuticals ha aumentado sus beneficios a una tasa media anual de 13.8%, mientras que los beneficios de la industria de Biotechs han experimentado un crecimiento de 12.7% anual. Los ingresos han ido creciendo a una tasa media de 22% al año. La rentabilidad financiera de Vertex Pharmaceuticals es de 20.6%, y sus márgenes netos son de 36.7%.

Información clave

13.8%

Tasa de crecimiento de los beneficios

13.7%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	22.0%
Rentabilidad financiera	20.6%
Margen neto	36.7%
Próxima actualización de resultados	06 May 2024

Actualizaciones de resultados anteriores recientes

We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings

Feb 22

Recent updates

Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'

Apr 11

Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely

Apr 05

Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth

Mar 21

Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?

Mar 15

Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run

Feb 28

We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings

Feb 22

Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Feb 07

Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range

Jan 22

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Jan 15

Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Dec 25

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued

Nov 13

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Oct 02

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate

Jul 31

We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease

Jul 03

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 22% Undervalued

Apr 30

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Apr 03

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 24% Undervalued

Jan 23

If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity

Jan 02

Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 47%?

Oct 24

Vertex to advance two AAT correctors to potentially treat rare, genetic disease

Oct 11

Do Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings Warrant Your Attention?

Oct 02

Vertex in licensing agreement with MaxCyte to use platform for gene editing candidate

Sep 28

Vertex Pharmaceuticals: Clinical Data Supports A Favorable Long-Term Growth Outlook

Sep 19

Vertex wins FDA label expansion for cystic fibrosis drug to add younger children

Sep 02

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Vertex Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:VRTX Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Dec 23	9,869	3,620	1,137
30 Sep 23	9,654	3,470	1,035
30 Jun 23	9,505	3,365	1,018
31 Mar 23	9,208	3,260	971
31 Dec 22	8,931	3,322	945
30 Sep 22	8,701	3,273	933
30 Jun 22	8,350	3,195	884
31 Mar 22	7,948	2,451	863
31 Dec 21	7,574	2,342	840
30 Sep 21	7,130	2,176	797
30 Jun 21	6,684	1,992	783
31 Mar 21	6,415	2,762	780
31 Dec 20	6,206	2,712	771
30 Sep 20	5,991	2,691	754
30 Jun 20	5,403	2,081	729
31 Mar 20	4,819	1,511	694
31 Dec 19	4,163	1,177	659
30 Sep 19	3,620	2,144	616
30 Jun 19	3,454	2,215	594
31 Mar 19	3,265	2,155	575
31 Dec 18	3,048	2,096	558
30 Sep 18	2,829	647	539
30 Jun 18	2,623	415	523
31 Mar 18	2,415	226	513
31 Dec 17	2,489	263	496
30 Sep 17	2,296	196	471
30 Jun 17	2,131	259	457
31 Mar 17	2,019	177	441
31 Dec 16	1,702	-112	433
30 Sep 16	1,661	-219	419
30 Jun 16	1,557	-275	413
31 Mar 16	1,292	-399	396
31 Dec 15	1,032	-556	377
30 Sep 15	759	-659	359
30 Jun 15	628	-734	334
31 Mar 15	600	-704	317
31 Dec 14	580	-738	305
30 Sep 14	787	-582	300
30 Jun 14	830	-530	308
31 Mar 14	1,002	-428	338
31 Dec 13	1,212	-504	356
30 Sep 13	1,195	-559	394
30 Jun 13	1,309	-499	408

Ingresos de calidad: VRTX tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio(36.7%) de VRTX son inferiores a los del año pasado (37.2%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de VRTX han crecido un 13.8% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de VRTX en el último año (9%) está por debajo de su media de 5 años (13.8% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de VRTX en el último año (9%) superó al de la industria Biotechs -8.9%.

Rentabilidad financiera

Alta ROE: La rentabilidad financiera (20.6%) de VRTX se considera alta.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Vertex Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 4/6

Información clave

Actualizaciones de resultados anteriores recientes

Vertex Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 06, 2024

We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings

Full year 2023 earnings: EPS exceeds analyst expectations

Vertex Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 05, 2024

Vertex Pharmaceuticals Incorporated to Report Q3, 2023 Results on Nov 06, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Vertex Pharmaceuticals Announces European Commission Approval for KALYDECO to Treat Infants with Cystic Fibrosis Ages 1 Month and Older

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion.

Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'

Vertex Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 06, 2024

Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 15, 2024

Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely

Vertex Pharmaceuticals Incorporated Announces New Drug Submission for Exagamglogene Autotemcel (Exa-Cel) Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth

Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?

Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run

Vertex Pharmaceuticals Receives CHMP Positive Opinion for KALYDECO for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older

We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings

Executive VP & COO notifies of intention to sell stock

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Positive Results from Pivotal Trials of Vanza Triple Combination Treatment for Cystic Fibrosis

Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Full year 2023 earnings: EPS exceeds analyst expectations

Vertex Pharmaceuticals Incorporated Provides Product Revenue Guidance for the Full Year 2024

Vertex Announces Positive Results from the VX-548 Phase 3 Program for the Treatment of Moderate-To-Severe Acute Pain

Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range

Vertex Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 05, 2024

Vertex Pharmaceuticals Incorporated Announces US FDA Approval of CASGEVY™ (Exagamglogene Autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Vertex Pharmaceuticals Incorporated Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Kingdom of Saudi

Executive VP & CFO notifies of intention to sell stock

Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Executive Chairman notifies of intention to sell stock

Vertex Pharmaceuticals Incorporated Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States

Vertex Pharmaceuticals Incorporated Appoints Nancy Thornberry to Its Board of Directors as an Independent Director

Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older

Vertex Pharmaceuticals Incorporated Announces European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5

Vertex Pharmaceuticals Incorporated Announces United Kingdom Medicines and Healthcare Products Regulatory Agency Granted Conditional Marketing Authorization for CASGEVY

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued

Lead Independent Director notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Market Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 To 5 Years With at Least One F508del Mutation

Vertex Pharmaceuticals Incorporated to Report Q3, 2023 Results on Nov 06, 2023

Vertex Pharmaceuticals Incorporated Appoints Michel Lagarde to Its Board of Directors

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Vertex Pharmaceuticals Incorporated Receives Chmp Positive Opinion for Kaftrio® (Ivacaftor/Tezacaftor/Elexacaftor) in Combination with Ivacaftor for Children with Cystic Fibrosis Ages 2 Through 5

Vertex Pharmaceuticals Incorporated Appoints E. Morrey Atkinson, Ph.D., as Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations

Now 20% undervalued after recent price drop

Vertex Pharmaceuticals Incorporated Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate

Now 21% undervalued

Lead Independent Director notifies of intention to sell stock

Vertex Pharmaceuticals Incorporated Announces European Commission Approval for ORKAMBI® (Lumacaftor/Ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 1 to <2 Years Old

We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease

Insufficient new directors

Vertex Pharmaceuticals Incorporated Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions

Now 20% undervalued

Executive VP & COO notifies of intention to sell stock

Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Now 21% undervalued

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

CEO, President & Director notifies of intention to sell stock

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 22% Undervalued

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Executive VP & CFO notifies of intention to sell stock

Executive VP & CFO notifies of intention to sell stock

Insider notifies of intention to sell stock

Executive VP & COO notifies of intention to sell stock

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) announces an Equity Buyback for $3,000 million worth of its shares.

Now 23% undervalued after recent price drop

Desglose de ingresos y gastos
Beta